Provided by Tiger Trade Technology Pte. Ltd.

Sarepta Therapeutics

20.52
-1.5000-6.81%
Post-market: 20.530.0100+0.05%19:30 EDT
Volume:2.20M
Turnover:45.53M
Market Cap:2.17B
PE:-15.59
High:22.02
Open:22.02
Low:20.28
Close:22.02
52wk High:25.32
52wk Low:14.68
Shares:105.57M
Float Shares:99.05M
Volume Ratio:0.53
T/O Rate:2.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3161
EPS(LYR):-7.1300
ROE:-9.48%
ROA:-1.13%
PB:1.42
PE(LYR):-2.88

Loading ...

Urban-gro, DraftKings, Sarepta Therapeutics, Destiny Tech100 And AMD: Why These 5 Stocks Are On Investors' Radars Today

Benzinga_recent_news
·
Mar 26

U.S. Small Caps Rise; Sarepta Therapeutics Climbs Highest

Dow Jones
·
Mar 26

Sarepta price target raised to $25 from $20 at Morgan Stanley

TIPRANKS
·
Mar 26

BUZZ-U.S. STOCKS ON THE MOVE-ADMA Biologics, Nanobiotix, DraftKings

Reuters
·
Mar 26

Sarepta Therapeutics Up Over 30%, on Pace for Largest Percent Increase Since May 2023 -- Data Talk

Dow Jones
·
Mar 26

These Stocks Are Today's Movers: Arm, Intel, Firefly Aerospace, Robinhood, Sarepta, JD.com, and More -- Barrons.com

Dow Jones
·
Mar 26

Shares of This Gene Therapy Maker Are Up 29%. The Safety Debate Is Far From Over. -- Barrons.com

Dow Jones
·
Mar 26

Sarepta initial siRNA data ‘thin and somewhat mixed,’ says Leerink

TIPRANKS
·
Mar 25

Sarepta early DM1 data ‘appear promising,’ says Oppenheimer

TIPRANKS
·
Mar 25

Sarepta Therapeutics' Early Trial Results of siRNA Treatments Show High Muscle Concentrations in Neuromuscular Diseases

MT Newswires Live
·
Mar 25

Shares of Sarepta Therapeutics up 3.2% Premarket After Muscle Disease Drugs Show Promise in Early-to-Mid Stage Trials

THOMSON REUTERS
·
Mar 25

BRIEF-Sarepta Announces First Clinical Data From Sirna Pipeline Targeting Fshd1 And Dm1

Reuters
·
Mar 25

BUZZ-Sarepta rises after muscle disease drugs show promise in early-to-mid stage trials

Reuters
·
Mar 25

Sarepta Therapeutics Inc - Proof-of-Concept Data Show Single Dose of Srp-1001 and Srp-1003 Reduces Target Protein or Mrna

THOMSON REUTERS
·
Mar 25

Sarepta Therapeutics Inc - Majority of Adverse Events in Studies Were Mild to Moderate and Not Dose Dependent

THOMSON REUTERS
·
Mar 25

Sarepta Therapeutics Inc - Sirna Achieves High Muscle Concentrations Without Dose Limiting Toxicity for Fshd1 and Dm1

THOMSON REUTERS
·
Mar 25

Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Rezolute (RZLT) and Demant (OtherWILLF)

TIPRANKS
·
Mar 25

Sarepta to present Phase 1/2 data for SRP-1001 in FSHD1 and SRP-1003 in DM1

Reuters
·
Mar 25

Sarepta pre-May sNDA plan points to constructive FDA dialogue, says Oppenheimer

TIPRANKS
·
Mar 19

Sarepta provides regulatory update on Amondys 45, Vyondys 53

TIPRANKS
·
Mar 19